The estimated Net Worth of Preston Klassen is at least $1.2 Milione dollars as of 26 January 2023. Dr Klassen owns over 380,605 units of Metacrine stock worth over $268,189 and over the last 11 years he sold MTCR stock worth over $178,422. In addition, he makes $749,375 as Pres e CEO & Director at Metacrine.
Sign up
Dr S MTCR stock SEC Form 4 insiders trading
Dr has made over 5 trades of the Metacrine stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 380,605 units of MTCR stock worth $156,048 on 26 January 2023.
The largest trade he's ever made was selling 380,605 units of Metacrine stock on 26 January 2023 worth over $156,048. On average, Dr trades about 21,418 units every 67 days since 2014. As of 26 January 2023 he still owns at least 541,905 units of Metacrine stock.
You can see the complete history of Dr Klassen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Preston S. Klassen M.D., M.H.S. biography
Dr. Preston S. Klassen M.D., M.H.S. is the Pres, CEO & Director at Metacrine.
What is the salary of Dr S?
As the Pres e CEO & Director of Metacrine, the total compensation of Dr S at Metacrine is $749,375. There are no executives at Metacrine getting paid more.
How old is Dr S?
Dr S is 52, he's been the Pres e CEO & Director of Metacrine since . There are 1 older and 3 younger executives at Metacrine. The oldest executive at Metacrine, Inc. is Michael B. York, 56, who is the Chief Bus. Officer.
What's Dr S's mailing address?
Preston's mailing address filed with the SEC is C/O REGULUS THERAPEUTICS INC., 4224 CAMPUS POINT CT., #210, SAN DIEGO, CA, 92121.
Insiders trading at Metacrine
Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell e Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.
What does Metacrine do?
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
What does Metacrine's logo look like?
Complete history of Dr Klassen stock trades at Arena Pharmaceuticals Inc, Conatus Pharmaceuticals, Regulus Therapeutics Inc e Metacrine
Metacrine executives and stock owners
Metacrine executives and other stock owners filed with the SEC include:
-
Dr. Preston S. Klassen M.D., M.H.S.,
Pres, CEO & Director -
Dr. Preston S. Klassen,
Pres, CEO & Director -
Patricia M. Millican,
Chief Financial Officer -
Catherine C. Lee,
Consultant -
Michael B. York,
Chief Bus. Officer -
Theresa Lowry,
VP of HR -
Patricia Millican,
Chief Financial Officer -
Andrew Guggenhime,
Director -
Jeffrey David Jonker,
Director -
John G Mc Hutchison,
Director -
Venture Fund Viii, L.P.Arch...,
-
Kristina Burow,
Director -
Preston Klassen,
Director -
Enterprise Associates 16, L...,
-
Trisha Millican,
Chief Financial Officer -
Forest Baskett,
10% owner -
Ali Behbahani,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ronald M Evans,
Director -
Carmen Chang,
10% owner -
Mohamad Makhzoumi,
10% owner -
Amir Nashat,
Director -
Management Co. Vii, L.L.C.P...,
-
Joshua Makower,
10% owner -
Scott D Sandell,
10% owner -
Peter W. Sonsini,
10% owner -
Paul Edward Walker,
10% owner -
Global Strategic Fund, L.P....,
-
Robert J Adelman,
-
Hubert C Chen,
Chief Medical Officer -
Catherine Chai Zon Lee,
EVP, Gen. Counsel & Secretary -
Julia C. Owens,
Director -
Richard A. Heyman,
Director -
Global Strategic Fund, L.P....,
-
Michael York,
Chief Business Officer -
Braden Michael Leonard,
10% owner